Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-01
2009-02-17
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S133000
Reexamination Certificate
active
07491734
ABSTRACT:
Compounds of formula I:wherein A, D, Ar1, E and Ar2are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
REFERENCES:
patent: 4657911 (1987-04-01), Imbert et al.
patent: 6492385 (2002-12-01), Myers et al.
patent: 7214688 (2007-05-01), Phillips et al.
patent: 2007/0078141 (2007-04-01), Wang et al.
patent: 2007/0191422 (2007-08-01), Ernst et al.
patent: 0190920 (1986-08-01), None
patent: 0327335 (1989-08-01), None
patent: 0546181 (1993-06-01), None
patent: 1219622 (2002-07-01), None
patent: 2529548 (1984-01-01), None
patent: 1416872 (1975-12-01), None
patent: WO 0136417 (2001-05-01), None
patent: WO 0192259 (2001-12-01), None
patent: WO 0192260 (2001-12-01), None
patent: WO 0192261 (2001-12-01), None
patent: WO 0198253 (2001-12-01), None
patent: WO 0215662 (2002-02-01), None
patent: WO 0216355 (2002-02-01), None
patent: WO 0216356 (2002-02-01), None
patent: WO 0216357 (2002-02-01), None
patent: WO 0216358 (2002-02-01), None
patent: WO 0217358 (2002-02-01), None
patent: WO 0220521 (2002-03-01), None
patent: WO 0244176 (2002-06-01), None
Schnürch et. al. “Cross-Coupling Reactions on Azoles with Two and More Heteroatoms” European Journal of Organic Chemistry 2006, 3283-3307.
Katritzky and Rees eds. Comprehensive Heterocyclic Chemistry vol. 6 Pergamon: New York, 1984, pp. 279-280.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface, pp. 1-15, 41 and pp. 279-308.
F. Ivy Carroll “Epibatidine structure-activity relationships” Bioorganic & Medicinal Chemistry Letters 2004 14, 1889-1896.
Huabei Zhang, Hua Li, Qinqin M. “QSAR study of a large set of 3-pyridyl ethers as ligands of the a4b2 nicotinic acetylcholine receptor.” Journal of Molecular Graphics and Modelling 2007, 26, 226-235.
STN International, file CAPLUS, CAPLUS accession No. 1993:213064, document No. 118:213064, Takeda Chemical Industries, Ltd: “preparation of five-membered heterocyclic amide derivatives,” JP, A2; 04247081, Sep. 3, 1992.
STN International, file CAPLUS, CAPLUS accession No. 1996:383036, document No. 125:167754, Brown, George R. et al: “Synthesis and Activity of a Novel Series of 3-Biarylquinuclidine Squalene Synthase Inhibitors,” J. Med. Chem. (1996), 39(15), 2971-2979.
“Reach-Through Claims” internet article published Apr. 12, 2002, Baker Botts LLP; http://bakerbotts.com
ews/inprint/reachthroughclaims.
U.S. Appl. No. 60/226,652, filed Aug. 21, 2000.
Phillips Eifion
Schmiesing Richard
AstraZeneca AB
Desai Rita J
Mitchell Kenneth F.
O'Dell David K
LandOfFree
2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110169